InnovAge vs Privia Health
INNV and PRVA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INNV and PRVA compare
Privia Health is the larger company, worth 2.4 times as much as InnovAge ($3.1B against $1.3B).
Privia Health grew revenue faster over the last twelve months (19.2% versus 15.9% for InnovAge).
Privia Health keeps more of each dollar of sales as profit, with a net margin of 1.4% compared with −0.26% at InnovAge.
Privia Health scores higher on the StockData Score (15 against 10 for InnovAge), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INNV | PRVA |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $3.1B |
| Share price | $9.50 | $24.04 |
| Change, 1 year | 88.1% | 2.7% |
| Change, 5 years | 13.0% | −16.7% |
| Beta (5Y) | 0.68 | 0.65 |
| Employees | 2,500 | 1,226 |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 | 3 |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 92.5× |
| P/S | 1.3× | 1.3× (better) |
| P/B | 5.5× | 3.8× (better) |
| EV/EBITDA | 50.8× | 42.0× (better) |
| P/FCF | 25.7× | – |
| FCF yield | 3.9% | – |
| Fair value | $5.78 | $15.41 |
| Margin of safety | −64.3% | −56.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 15.9% | 19.2% (better) |
| Revenue growth, 5Y average | 9.2% | 21.0% (better) |
| Net income growth (TTM) | – | 91.3% |
| EPS growth (TTM) | – | 100% |
| EPS growth, 5Y average | – | −11.4% |
| Profitability | ||
| Gross margin | 23.0% | – |
| Operating margin | 0.26% | 2.1% (better) |
| Net margin | −0.26% | 1.4% (better) |
| FCF margin | 5.1% | – |
| Return on equity | −1.1% | 4.6% (better) |
| Return on invested capital | 1.2% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.20 (better) | 0.00 |
| Net debt / EBITDA | −3.93 | – |
| Current ratio | 1.05 | 1.63 (better) |
| Altman Z-score | 4.24 | 4.54 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 13.5% | 96.7% |
| Held by insiders | – | 7.1% |
| Insider net buying, 12 months | −$227M | −$22.2M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 3.3% |
Go deeper
- INNV stock overview
- INNV income statement
- INNV valuation and score
- PRVA stock overview
- PRVA income statement
- PRVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.